Project Grant R01MH137501
Award Date
6/15/25
Completion Date
4/30/30
Dollars Obligated
$520K
Federal Agency
National Institute of Mental Health
Federal Grant Program
93.242
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
The National Institute of Mental Health (NIMH) awarded a $434,421 Project Grant (CFDA 93.242 Mental Health Research Grants) to The Feinstein Institutes for Medical Research to study the development of cerebellar-cortical functional connectivity in youth and its prediction of psychosis. The 4-year grant aims to: Chart the normal development of cerebellar-cortical connectivity from childhood to early adulthood using data from the Lifespan Human Connectome Project in Development. Investigate how...
The National Institute of Mental Health (NIMH) awarded a $480,834 Project Grant (CFDA 93.242 - Mental Health Research Grants) to The Feinstein Institutes for Medical Research to leverage electronic health records (EHRs) and other data sources to develop machine learning-based predictive models for key outcomes in psychosis-related disorders. The 5-year project aims to build models to forecast treatment response, illness severity, medical comorbidities, and diagnostic transitions. The research...
This Project Grant award from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) provides $1,217,886 to conduct a multi-center, randomized clinical trial to develop a decision support tool for using biomarkers to guide treatment of first-episode psychosis patients. The project, titled "Biomarkers to Enhance Early Schizophrenia Treatment (BEEST)," aims to evaluate whether using three specific biomarkers - a functional brain scan,...
The National Institute of Mental Health (NIMH) awarded a $665,508 Project Grant under the Mental Health Research Grants program (CFDA 93.242) to the Centre for Addiction and Mental Health (CAMH) in Toronto, Canada. The goal of this 5-year project is to develop a clozapine decision support tool that utilizes biomarkers to guide treatment for first-episode psychosis (FEP) patients at risk of poor response to conventional first-line antipsychotics. The project will characterize 410 FEP patients...
This federal Project Grant award from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants program (CFDA 93.242), provides $779,842 to The Mclean Hospital Corporation to conduct a multi-center, randomized clinical trial evaluating whether the use of biomarkers can lead to better outcomes for patients experiencing a first episode of psychosis (FEP). The key objectives are to develop a clozapine decision support tool based on three specific biomarkers: a...
This $784,642 Project Grant awarded by the National Institute of Mental Health (NIMH) under the Mental Health Research Grants (CFDA 93.242) program will support research at the New York Genome Center, Inc. (Nygc) to leverage electronic health records, dimensional phenotyping, and genomic analysis to develop predictive models for clinical outcomes in psychosis-related disorders. The key objectives are to: 1) Build machine learning models to forecast treatment response, illness severity, medical...
This $11.7 million Cooperative Agreement award from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) will fund the "Phenotypes Reimagined to Define Clinical Treatment and Outcome Research (PREDICTOR)" project. The project aims to develop clinical signatures for predicting key outcomes, such as treatment discontinuation, hospitalizations, and emergency room visits, in young people aged 15-30 seeking mental health treatment. The...
The National Institute of Mental Health (NIMH) awarded a $2,754,722 Cooperative Agreement (UG3MH137656) under the Mental Health Research Grants program (CFDA 93.242) to Weill Medical College of Cornell University. The project aims to develop and test a novel biomarker-guided approach for selecting the most effective treatment for individuals with treatment-resistant depression. This includes optimizing statistical classifiers using machine learning techniques to predict antidepressant...
The National Institute of Mental Health (NIMH) awarded a $334,588 Project Grant (CFDA 93.242 - Mental Health Research Grants) to Beth Israel Deaconess Medical Center, Inc. (Bidmc) to develop predictive models for identifying individuals at clinical high-risk for psychosis. The project aims to 1) determine if a collective intelligence approach involving a group of psychiatrists can outperform individual predictions based on clinical data, and 2) assess whether a multidisciplinary group...
This $812,950 Project Grant awarded by the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) will fund the "PSYCHEMERGE: ADVANCING PRECISION PSYCHIATRY" research project. The project aims to develop a nationwide federated transfer-learning platform for generalizable and bias-aware algorithms, integrate advanced genomic analysis methods with electronic health record data to uncover novel biology informing precision psychiatry, and...